Alpha Teknova AI Stock Analysis
Want to see TKNO full AI Analyst Report?
Alpha Teknova (TKNO) AI Stock Analysis
Alpha Teknova
(NASDAQ:TKNO)
Overall score reflects weak financial performance driven by ongoing losses and negative cash flow, partially offset by a constructive earnings outlook (raised 2026 guidance and improving margins/cash usage). Technicals are broadly neutral and valuation provides limited support given the negative P/E and no dividend.
Alpha Teknova (TKNO) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $541.00M
- Dividend Yield
- ―
- Average Volume (3M)
- 451.81K
- Price to Earnings (P/E)
- -29.2
- Beta (1Y)
- 2.05
- Revenue Growth
- 15.45%
- EPS Growth
- 12.64%
- Country
- US
- Employees
- 158
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Alpha Teknova Business Overview & Revenue Model
Company Description
Alpha Teknova, Inc. supplies vital scientific reagents to the life sciences sector across both the United States and international markets. These crucial materials play a key role in facilitating the exploration, evolution, and ultimate production of...
Alpha Teknova Earnings Call Summary
The call was strongly constructive. Teknova reported record revenue, 22% year-over-year growth, an 86% increase in Clinical Solutions revenue, improved gross margin and reduced cash usage, while raising its 2026 revenue guidance and strengthening its balance sheet with a $46 million equity raise. The main challenges were continued weakness in early-stage biotech and catalog demand, ongoing operating losses and cash outflow, and the fact that the biotech recovery remains early and not yet fully established.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Teknova increased 2026 total revenue guidance to $46 million to $48 million, implying approximately 16% revenue growth at the midpoint compared to 2025; it expects gross margin to land in the mid-to-upper 30s percentage range for the full year 2026 and is still targeting mid-to-high 30s percentage for gross margin for the full year of 2026, with Q4 expected to be similar in the mid-to-high 30s, while sales and marketing spend is expected to be approximately $2 million for the full year 2026 and operating expenses are forecast to be at least $8 million in the fourth quarter of 2026. Each additional dollar of revenue is estimated to drop through at a marginal cash rate of approximately 70%, adjusted EBITDA is expected to become positive in the range of $52 million to $57 million in annualized revenue, and if end markets are stronger in 2027 and stepped-up commercial investments bear fruit as anticipated, the company should report a positive adjusted EBITDA quarter before the end of 2027; free cash outflow is expected to be similar in the fourth quarter to the $1.4 million reported in the third quarter and less than $8 million for the full year 2026, while 2027 revenue guidance will be provided with full year 2026 results.
Alpha Teknova Financial Statement Overview
Summary
Mixed fundamentals. Revenue is growing modestly and losses have narrowed versus prior years, and leverage is relatively moderate; however, the company remains unprofitable with negative operating margins and still-negative operating/free cash flow, keeping financial quality below average.
Income Statement
34NegativeBalance Sheet
62PositiveCash Flow
28Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 45.95M | 40.52M | 37.74M | 36.68M | 41.42M | 36.89M |
| Gross Profit | 16.45M | 13.44M | 7.23M | 10.30M | 17.48M | 17.62M |
| EBITDA | -10.23M | -10.15M | -19.57M | -25.54M | -25.69M | -9.16M |
| Net Income | -15.97M | -17.26M | -26.75M | -36.78M | -47.47M | -9.80M |
Balance Sheet | ||||||
| Total Assets | 94.68M | 103.58M | 118.77M | 128.59M | 152.26M | 166.51M |
| Cash, Cash Equivalents and Short-Term Investments | 16.56M | 5.91M | 30.40M | 28.48M | 42.24M | 87.52M |
| Total Debt | 26.99M | 15.15M | 30.17M | 30.46M | 42.31M | 11.87M |
| Total Liabilities | 34.90M | 34.81M | 36.38M | 38.55M | 52.38M | 23.31M |
| Stockholders Equity | 59.78M | 68.78M | 82.39M | 90.04M | 99.89M | 143.20M |
Cash Flow | ||||||
| Free Cash Flow | -6.28M | -9.79M | -13.52M | -26.75M | -55.55M | -28.95M |
| Operating Cash Flow | -5.47M | -8.65M | -12.39M | -18.81M | -27.40M | -9.07M |
| Investing Cash Flow | 8.45M | 10.70M | -27.27M | -7.74M | -28.15M | -17.52M |
| Financing Cash Flow | 448.00K | 151.00K | 14.89M | 12.80M | 10.27M | 110.79M |
Alpha Teknova Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TKNO, the sentiment is Positive. The current price of 8.62 is above the 20-day moving average (MA) of 7.38, above the 50-day MA of 7.82, and above the 200-day MA of 5.07, indicating a bullish trend. The MACD of 0.16 indicates Negative momentum. The RSI at 59.54 is Neutral, neither overbought nor oversold. The STOCH value of 82.21 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TKNO.
Alpha Teknova Risk Analysis
Alpha Teknova disclosed 72 risk factors in its most recent earnings report. Alpha Teknova reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksAlpha Teknova Peers Comparison
Overall Rating
ETON82Outperform- TKNO50Neutral
EVO50Neutral
LFCR50Neutral
EBS45Neutral
ORGO39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ETON | 82Outperform | $1.95B | 38.75 | 104.82% | ― | 100.61% | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| TKNO | 50Neutral | $549.14M | -29.22 | -24.95% | ― | 15.45% | 12.64% |
| EVO | 50Neutral | $614.69M | -3.10 | -25.63% | ― | 0.31% | -19.37% |
| LFCR | 50Neutral | $241.46M | -3.39 | 381.59% | ― | ― | ― |
| EBS | 45Neutral | $311.06M | -1.20 | -61.33% | ― | -17.72% | -456.60% |
| ORGO | 39Underperform | $121.39M | -0.89 | -46.25% | ― | -24.33% | -1171.44% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TKNO | Alpha Teknova, Inc. | 8.62 | 4.19 | 94.58% | |
| EBS | Emergent Biosolutions | 6.04 | -4.28 | -41.47% | |
| LFCR | Lifecore Biomedical, Inc. | 6.40 | -1.49 | -18.88% | |
| EVO | Evotec Ag (Adr) | 1.69 | -1.48 | -46.69% | |
| ORGO | Organogenesis Holdings | 1.05 | -5.16 | -83.09% | |
| ETON | Eton Pharmaceuticals | 68.40 | 51.52 | 305.21% |
Alpha Teknova Corporate Events
Alpha Teknova announces underwritten equity offering to fund growth
PositiveOn October 20, 2026, Alpha Teknova entered an underwriting agreement with TD Securities (USA) LLC and William Blair & Company for an underwritten public offering of 8,000,000 shares of common stock at a public price of $5.00 per share. Underwriters w...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 05, 2026